Bank of New York Mellon’s Travere Therapeutics TVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$14M Buy
246,485
+29,259
+13% +$1.3M ﹤0.01% 1843
2026
Q1
$6.45M Sell
217,226
-2,770
-1% -$82.8K ﹤0.01% 2176
2025
Q4
$8.41M Sell
219,996
-17,247
-7% -$561K ﹤0.01% 2029
2025
Q3
$5.67M Buy
237,243
+6,098
+3% +$115K ﹤0.01% 2242
2025
Q2
$3.42M Sell
231,145
-2,797
-1% -$46.4K ﹤0.01% 2484
2025
Q1
$4.19M Buy
233,942
+17,079
+8% +$347K ﹤0.01% 2316
2024
Q4
$3.78M Buy
216,863
+7,513
+4% +$133K ﹤0.01% 2433
2024
Q3
$2.93M Sell
209,350
-55,466
-21% -$578K ﹤0.01% 2571
2024
Q2
$2.18M Buy
264,816
+41,048
+18% +$276K ﹤0.01% 2749
2024
Q1
$1.73M Sell
223,768
-14,232
-6% -$120K ﹤0.01% 2839
2023
Q4
$2.14M Sell
238,000
-7,978
-3% -$58.1K ﹤0.01% 2799
2023
Q3
$2.2M Sell
245,978
-2,168
-0.9% -$30.6K ﹤0.01% 2760
2023
Q2
$3.81M Buy
248,146
+31,377
+14% +$571K ﹤0.01% 2470
2023
Q1
$4.88M Buy
216,769
+3,546
+2% +$75.4K ﹤0.01% 2310
2022
Q4
$4.48M Sell
213,223
-895
-0.4% -$19K ﹤0.01% 2399
2022
Q3
$5.28M Buy
214,118
+23,617
+12% +$610K ﹤0.01% 2265
2022
Q2
$4.62M Sell
190,501
-30,286
-14% -$762K ﹤0.01% 2359
2022
Q1
$5.69M Sell
220,787
-1,301
-0.6% -$34.5K ﹤0.01% 2352
2021
Q4
$6.89M Sell
222,088
-1,162
-0.5% -$32.7K ﹤0.01% 2294
2021
Q3
$5.41M Buy
223,250
+19,796
+10% +$364K ﹤0.01% 2447
2021
Q2
$2.97M Sell
203,454
-2,958
-1% -$58.3K ﹤0.01% 2756
2021
Q1
$5.15M Buy
206,412
+10,723
+5% +$296K ﹤0.01% 2438
2020
Q4
$5.33M Buy
195,689
+4,112
+2% +$96K ﹤0.01% 2327
2020
Q3
$3.54M Buy
191,577
+10,632
+6% +$207K ﹤0.01% 2399
2020
Q2
$3.69M Sell
180,945
-5,847
-3% -$93.1K ﹤0.01% 2359
2020
Q1
$2.73M Buy
186,792
+47
+0% +$707 ﹤0.01% 2387
2019
Q4
$2.65M Buy
186,745
+6,208
+3% +$79.3K ﹤0.01% 2649
2019
Q3
$2.09M Buy
180,537
+2,272
+1% +$37.5K ﹤0.01% 2737
2019
Q2
$3.58M Sell
178,265
-2,461
-1% -$48.6K ﹤0.01% 2496
2019
Q1
$4.09M Buy
180,726
+2,697
+2% +$59.6K ﹤0.01% 2432
2018
Q4
$4.03M Sell
178,029
-180,708
-50% -$4.5M ﹤0.01% 2421
2018
Q3
$10.3M Sell
358,737
-3,286
-0.9% -$93.9K ﹤0.01% 2011
2018
Q2
$9.87M Sell
362,023
-23,680
-6% -$631K ﹤0.01% 2027
2018
Q1
$8.63M Sell
385,703
-10,048
-3% -$239K ﹤0.01% 2057
2017
Q4
$8.34M Sell
395,751
-48,067
-11% -$1.1M ﹤0.01% 2077
2017
Q3
$11M Buy
443,818
+9,119
+2% +$201K ﹤0.01% 1941
2017
Q2
$8.43M Buy
434,699
+46,967
+12% +$852K ﹤0.01% 2069
2017
Q1
$7.16M Sell
387,732
-4,559
-1% -$89.2K ﹤0.01% 2149
2016
Q4
$7.43M Sell
392,291
-22,216
-5% -$454K ﹤0.01% 2121
2016
Q3
$9.28M Sell
414,507
-108,199
-21% -$2.06M ﹤0.01% 1918
2016
Q2
$9.31M Sell
522,706
-16,188
-3% -$262K ﹤0.01% 1892
2016
Q1
$7.36M Buy
538,894
+32,751
+6% +$497K ﹤0.01% 1989
2015
Q4
$9.76M Buy
506,143
+81,270
+19% +$1.62M ﹤0.01% 1856
2015
Q3
$8.61M Sell
424,873
-29,862
-7% -$885K ﹤0.01% 1945
2015
Q2
$15.1M Buy
454,735
+331,392
+269% +$9.08M ﹤0.01% 1690
2015
Q1
$2.96M Buy
123,343
+22,317
+22% +$340K ﹤0.01% 2610
2014
Q4
$1.24M Sell
101,026
-1,081
-1% -$11.2K ﹤0.01% 3167
2014
Q3
$921K Buy
102,107
+21,992
+27% +$259K ﹤0.01% 3341
2014
Q2
$941K Buy
80,115
+28,325
+55% +$384K ﹤0.01% 3348
2014
Q1
$1.1M Buy
+51,790
New +$796K ﹤0.01% 3226

Other funds holding TVTX

Bank of New York Mellon's TVTX Position: Q2 2026 in Review

Bank of New York Mellon increased its Travere Therapeutics (TVTX) stake by 13% in Q2 2026, buying an estimated $1.3M and bringing the position to 246,485 shares worth $14M. The position accounts for ﹤0.01% of the portfolio, ranked #1843.

Bank of New York Mellon first reported a position in TVTX in Q1 2014 and has held it in 50 quarters since. The position peaked at $15.1M in Q2 2015. 218 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Bank of New York Mellon held 246,485 shares of Travere Therapeutics worth $14M as of Q2 2026.
  • Bank of New York Mellon bought 29,259 Travere Therapeutics shares in Q2 2026, an estimated $1.3M.
  • Travere Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1843 holding.
  • Bank of New York Mellon first reported a position in Travere Therapeutics in Q1 2014 and has held it in 50 quarters since.
  • Bank of New York Mellon's Travere Therapeutics position peaked at $15.1M in Q2 2015.
  • 218 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.